Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce the successful conclusion of negotiations with the pan ...

As treatment for spinal muscular atrophy (SMA) has drastically improved over the last decade, so too have survival rates and the number of people with SMA living well into adulthood. | A new education ...

Switzerland’s medical products authority has granted the first approval for a malaria medicine designed for small infants, ...

A new treatment for malaria in babies and very small children has just been approved; we hear more about the drug expected to save many lives.

Novartis said on Tuesday it had received approval in Switzerland for Coartem Baby, which it said was the first drug to treat ...

Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug ...

Swissmedic gave a green light Tuesday for the medicine from Basel-based pharmaceutical company Novartis for treatment of ...

Novartis on Tuesday said it had received approval in Switzerland for Coartem Baby, which it said was the first drug to treat ...

Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global ...

Novartis worked in collaboration with the Medicines for Malaria Venture (MMV), a Swiss-based nonprofit that works to prevent ...

Switzerland's medical products authority has granted the first approval for a malaria medicine designed for small infants.

Novartis has grown in renal diseases once again with a $1.7bn deal to buy Regulus and its autosomal dominant polycystic kidney disease (ADPKD) drug.